Sugi Predict

Sugi Predict / Compounds / SCHEMBL897183

SCHEMBL897183

SCHEMBL897183

Cc1cc(NC(=O)Oc2ccccc2)no1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.61
▸ NPC1 O15118 6/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ GAA P10253 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.59
▸ LMNA P02545 1/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HPGD P15428 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14147271 0.85 RAB9A (0.58) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL1012012 0.82 SMN1; SMN2 (0.54) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL5221892 0.81 RAB9A (0.49) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL769541 0.81 RAF1 (0.64) RAB9ANPC1MEN1KMT2ANPSR1
SCHEMBL3080087 0.81 RAB9A (0.67) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL1012633 0.81 ALDH1A1 (0.51) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL1015499 0.79 RAF1 (0.52) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL1010348 0.79 FAAH (0.45) MEN1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL11643675 0.79 MAPT (0.62) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4903102 0.78 RAF1 (0.48) RAB9ANPC1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049059-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB SYNTHON BV (NL) 2026-02-19 — — US disclosed
EP-4654968-A1 PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF Alivus Life Sciences Limited (IN) 2025-12-03 — — EP disclosed
EP-4622961-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB Synthon B.V. (NL) 2025-10-01 — — EP disclosed
WO-2024251182-A1 QUINOXALINE COMPOUND AND USE THEREOF 广州六顺生物科技有限公司 2024-12-12 — — WO disclosed
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
WO-2024157170-A1 PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF GLENMARK LIFE SCIENCES LIMITED (IN) 2024-08-02 — — WO disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
WO-2024110606-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB SYNTHON B.V. (NL) 2024-05-30 — — WO disclosed
WO-2024110606-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB SYNTHON B.V. (NL) 2024-05-30 — — WO disclosed
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
EP-1415987-A1 NITROGENOUS AROMATIC RING COMPOUNDS Eisai Co., Ltd. (JP) 2004-05-06 — — EP disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 — — US disclosed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 — — US disclosed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 — — WO disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 — — WO disclosed
EP-0099770-B1 OXAZINOBENZOTHIAZINE-6,6-DIOXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENT PROVESAN S.A. (CH) 1986-08-27 — — EP disclosed
US-4563452-A ANTIINFLAMMATORY, ANALGESIC PROVESAN S.A. (CH) 1986-01-07 — — US disclosed
EP-0099770-A1 Oxazinobenzothiazine-6,6-dioxide derivatives, their preparation and their use as medicament PROVESAN S.A. (CH) 1984-02-01 — — EP disclosed
US-4396621-A ANALGESICS, ANTIIMFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1983-08-02 — — US disclosed
EP-0044185-A2 Imidazolidinone derivatives ELI LILLY AND COMPANY (US) 1982-01-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 RAB9A 1449/4885NPC1 1654/4885MEN1 2842/4885
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R RAB9A 3247/4885NPC1 1179/4885MEN1 3116/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RAB9A 2987/4885NPC1 414/4885MEN1 1766/4885
US-20260049059-A1 A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB KRAS, PDGFRB, BRAF RAB9A 509/4885NPC1 1713/4885MEN1 1059/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 RAB9A 3372/4885NPC1 241/4885MEN1 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.